Therapeutic effect of liraglutide on expression of CTGF and BMP-7 in induced diabetic nephropathy.
J Cell Biochem · 2019
Last updated 2026-05-28In a study of 60 rats with diabetes-related kidney disease, those given the GLP-1 drug liraglutide showed improvements in kidney function and structure. Liraglutide reduced a harmful protein (CTGF) by 30% and increased a protective protein (BMP-7) by 40%, while also lowering blood sugar and markers of kidney damage.
AI summary of the abstract below.
| Journal | J Cell Biochem, 2019 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.10 |
| NIH percentile | 7 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes, Chronic Kidney Disease |
Abstract
INTRODUCTION: Diabetic nephropathy (DN) is one of the critical complications of diabetes mellitus and the main cause of chronic renal dysfunction. The pathogenic mechanism causing the disease remains unclear and there is a lack of effective treatment methods so novel strategies are needed for DN management. The aim of this study, therefore, is to evaluate the effect of liraglutide as glucagon-like peptide-1 analogue and its underlying mechanisms on induced DN in rats MATERIALS AND METHODS: Sixty rats were divided into control group, diabetic group, and liraglutide-treated group. At the end of experiment, renal CTGF and BMP-7 messeger RNA expression were determined. Blood sugar, serum urea, and creatinine were measured. Also, histopathological changes were studied.
RESULTS: Liraglutide can improve renal alterations associated with diabetes as it reduced CTGF expression and increased BMP-7 expression. In the same time, it could improve histopathological changes and renal function tests.
CONCLUSION: These findings influence the beneficial use of liraglutide for the management of DN in patients with diabetes mellitus.
Verbatim abstract via PubMed 31127659 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.